

Letter from the Board of Directors

In 2020, R1 launched its ESG journey with our unequivocal support and dedicated oversight. Now, we are pleased to share and reflect on the company's progress in building and strengthening its ESG program and journey in 2021.

As Directors, we are deeply committed to advancing a best-in-class ESG program befitting of a leading company that serves patients and providers with a solutions-first mindset. From a governance standpoint, ESG is woven into the fabric of our Board commitments with a dedicated Board ESG liaison partnering with the company's ESG steering workgroup, standing ESG reporting in the committee setting as set forth in R1's Board charters and meeting cadence, and continuous, direct shareholder engagement. We believe that achieving and sustaining business excellence is intrinsically tied to leading by example through corporate responsibility that reflects our company's commitment to stakeholder engagement and transparency.

At R1, continuous business success is borne from dedication to excellence, expertise in execution, and collective commitment to a culture grounded in the R1 Way.

At R1, continuous business success is borne from dedication to excellence, expertise in execution, and collective commitment to a culture grounded in the R1 Way. We are proud to highlight in this report the many examples of the company's achievements in ESG areas throughout 2021. In championing R1's ESG commitment, we are delighted to play an active governance role providing oversight and support for the company's ESG continuous journey.


Agnes Bundy Scanlan


John B. Henneman, III
Lead Director


Jill Smith


David M. Dill


Alex J. Mandl


Anthony J. Speranzo
Chair of the Board


Michael C. Feiner


Neal Moszkowski


Dr. Anthony R. Tersigni


Joseph Flanagan


Ian Sacks


Albert Zimmerli